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Ketorolac is a potent anti-inflammatory drug. Chemically, it is pyrrolizine carboxylic
acid provided as a recemic mixture. This non-steroidal and non-narcotic drug is admin-
istered systemically (via oral and parenteral route) for the control of mild to moderate
pain as well as of some postoperative and cancer pain (1). It inhibits the synthesis of
prostaglandin by inhibiting the enzyme cyclooxygenase (COX). Administration of this
non-selective COX inhibitor by oral route causes many gastrointestinal side effects, like
nausea, vomiting, gastric irritation, peptic ulceration and bleeding that limit its clinical
use (2). Gastrointestinal (GI) side effects produced by NSAIDs are either due to direct
contact or indirect effect of the drug on the gastrointestinal mucus membrane. Acidic na-
ture of NSAIDs, ion trapping and inhibition of cytoprotective prostaglandins are some
of the reasons for the GI adverse effects (3–5). Literature reveals that conjugation of a
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Ketorolac is a non-steroidal anti-inflammatory drug.
Dextran conjugates of ketorolac (KD) were synthesized
and characterized to improve ketorolac aqueous solubi-
lity and reduce gastrointestinal side effects. An N-acyl-
imidazole derivative of ketorolac (KAI) was condensed
with a model carrier polymer, dextran of different mo-
lecular masses (40000, 60000, 110000 and 200000). IR
spectral data confirmed formation of ester bonding.
Ketorolac contents were evaluated by UV-spectrophoto-
metric analysis. The molecular mass was determined by
measuring viscosity using the Mark-Howink-Sakurada
equation. In vitro hydrolysis studies were performed in
aqueous buffers (pH 1.2, 7.4, 9) and in 80% (V/V) human
plasma (pH 7.4). At pH 9, a higher rate of ketorolac re-
lease from KD was observed as compared to aqueous
buffer of pH 7.4 and 80% human plasma (pH 7.4), fol-
lowing first-order kinetics. In vivo biological screening in
mice and rats indicated that conjugates retained analge-
sic and anti-inflammatory activities with significantly re-
duced ulcerogenicity compared to the parent drug.
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polymeric carrier with drugs to form a polymeric or macromolecular prodrug might be
one a useful approach to improve physicochemical properties and clinical acceptance of
a drug (6–9). These can be obtained by conjugation of a drug to a biodegradable poly-
mer by chemical linkage. The parent drug is then released in vivo through biotransfor-
mation.
The polysaccharide dextran can be used as a model carrier due to its physiological
acceptance and excellent physicochemical characteristics such as high aqueous solubility
with low toxicity, abundant hydroxyl groups for drug conjugation and availability in a
wide range of molecular masses (10, 11). Larsen et al. (12, 13) reported many dextran
conjugates of NSAIDs (diclofenac, ibuprofen, ketoprofen, naproxen, fenoprofen) for their
improved physicochemical properties. Potential application of dextran-5-aminosalicylic
acid (5-ASA) conjugates was suggested in the treatment of Crohn’s disease (14). Flur-
biprofen-dextran conjugates showed reduction in ulcerogenicity compared to flurbipro-
fen alone (15). Dextran conjugates of fluorouracil have been proposed for targeting and
controlled release (16). Encouraging clinical outcomes were observed by Bue et al. (17);
epidermal growth factor-dextran (EGF-dextran) could be effective as intravesical therapy,
either conjugated with cystostatic drugs or labeled with suitable radionuclides. In the pres-
ent work, dextran conjugates of ketorolac were synthesized and evaluated for their poten-
tial use as a polymeric prodrug for oral drug delivery. In vivo investigations in animals were
performed to assess their pharmacological activities and gastrointestinal toxicity.
EXPERIMENTAL
Materials
Ketorolac tromethamine was a generous gift from Dr. Reddy’s Lab. Ltd. (India).
Dextran of different molecular masses and N,N’-carbonyldiimidazole (CDI) were pur-
chased from Fluka Biochemika (Switzerland). Purity of the compounds was tested on
Silica gel-G coated TLC plates (Merck, India) using iodine vapor as visualizing agent.
Carrageenean was purchased from HiMedia Laboratories Pvt. Ltd. (India). Other chemi-
cals were of synthetic grade.
Hydrochloric acid buffer (KCl + HCl, pH 1.2), phosphate buffer (KH2PO4 + NaOH,
pH 7.4) and borrate buffer (KCl + H3BO3 + NaOH, pH 9) were used.
Preparation of free ketorolac
Free ketorolac was obtained from its tromethamine salt by precipitation and recrys-
tallization. To a 5% (m/V) aqueous solution of ketorolac tromethamine, 1 mol L–1 HCl was
added dropwise with stirring; solid ketorolac precipitated. This precipitate was then ex-
tracted with ethyl acetate and solvent was evaporated to dryness. Free ketorolac acid
was obtained by recrystallization from a mixture of ethyl acetate/ether (1:1).
Melting point was measured in an open capillary tube and is uncorrected. The pu-
rity of ketorolac was achieved by thin layer chromatography (the mobile phase was
made of chloroform/methanol, 10:1) and UV spectra were recorded on a double beam
UV-Vis spectrophotometer-160 (Shimadzu, Japan).
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Synthesis of ketorolac-dextran conjugates
To a solution of ketorolac (0.5 g, 1.96 × 10–3 mol, in dry DMSO, 4 mL), CDI was ad-
ded (0.45 g, 2.78 × 10–3 mol) slowly in portions for 30 minutes maintaining the tempera-
ture of the reaction at 0 °C. A solution of dextran of different molecular masses (40000,
60000, 110000 and 200000) (1 g in dry DMSO, 15 mL) was added to the above mixture
with stirring, maintaining the reaction at 10 °C for 30 min and then it continued for 3
days at room temperature in a dry area with occasional stirring. The conjugates were
precipitated by addition of a methanol/diethyl ether (1:1) mixture 4–5 times remove un-
conjugated drug and then washed with acetone to obtain ketoralac-dextran conjugates
KD1, KD2, KD3 and KD4 (Scheme 1).
Characterization of ketorolac-dextran conjugates
Characterization data of KDs are presented in Table I. TLC on silica gel-G plates
confirmed purity and absence of entrapped free drug in the conjugates. Chloroform/
methanol (10:1) was used as mobile phase and iodine vapors were used for spot detec-
tion. The lmax in borate buffer (pH 9) was found at 323.8 nm.
To confirm the conjugate formation, IR spectra of the samples were recorded on a
Perkin-Elmer IR spectrophotometer (UK) in potassium bromide discs (Fig. 1).
Elemental analyses (C, H, N) were carried out on a Carlo-Erba model 1108 analyzer
(Italy).
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a Amount of parent drug in mg per 100 mg of drug-dextran conjugate.
b Calculated on the basis of drug content.
Average molecular mass was evaluated by intrinsic viscosity measurements of the
conjugates (2%, m/V aqueous solution) using a capillary viscometer (Ostwald, India) at
27 °C (single measurement at one concentration). Intrinsic viscosities were estimated by
using Eq. (1). Average molecular masses were then calculated by the Mark-Howink-
Sakurada equation (18) expressed as Eq. (2):
[h] = [hrel – 1] / [c + 0.28 c (hrel – 1)] (1)
log [h] = log K + a log M (2)
where [h] represents intrinsic viscosity, hrel relative viscosity at concentration c (%, m/V),
M is molecular mass, K and a are the constants.
Drug content
The ketorolac concentration (mg per 100 mg dextran conjugate) was estimated. Ke-
torolac-dextran conjugate (1 mg mL–1) in aqueous borate buffer (pH 9) was maintained
at 70 °C for 1 h. The solution was then left aside for 24 h at room temperature (r.t.) for
complete hydrolysis. After neutralization with 1 mol L–1 HCl, the released ketorolac was
extracted in chloroform and estimated by measuring the absorbance at 311 nm. Absence
of ketorolac in aqueous layer was achieved by no absorption of conjugate or ketorolac in
the aqueous layer at the characteristic wavelength.
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Fig. 1. IR spectra: (A) – dextran, (B) – ketorolac and (C)– ketorolac dextran conjugate.
In vitro hydrolysis
At pH 9. – Ten aliquots of 10 mg of KD were dissolved in 10 mL of borate buffer (pH
9) in test tubes. The reaction temperature was maintained at 37 ± 1 °C in a water bath.
Test tubes were withdrawn at regular time intervals of 0.1, 0.2, 0.3, 0.4…to 1 h, cooled to
r.t. and neutralized with 1 mol L–1 HCl. Ketorolac regenerated upon hydrolysis was ex-
tracted in chloroform and determined at 311 nm.
At pH 1.2, 7.4 and in 80% human plasma (pH 7.4). – Samples of KD (1 mg mL–1) in
aqueous medium (pH 1.2 or pH 7.4 or 80% human plasma, pH 7.4) were maintained at 37
± 1 °C. Aliquots were withdrawn after fixed intervals of 0.5, 1, 2, and 3 h and the released
parent drug was estimated using the same method as described for hydrolysis at pH 9.
Biological evaluation
In vivo animal studies were carried out according to the guidelines of IAEC (Institu-
tional Animal Ethics Committee, M. G. M. Medical College, India). Wistar rats (150–200 g)
and Swiss albino mice (20–25 g) of either sex were used for biological screening. Ani-
mals were acclimatized to laboratory conditions for at least 3 days before commence-
ment of the experiments and were kept under a 12 h light/12 h dark cycle. Animals were
fasted overnight prior to treatment and received free access to water during the experi-
ment. Doses of KD1-KD4 were equimolar to the parent drug (ketorolac), which was cal-
culated on the basis of their drug content in the conjugates. All the drugs were prepared
in 2% gum acacia and administered orally (p.o. route).
Analgesic activity. – Acute analgesia produced by the drugs was assessed by the acetic
acid induced writhing method in mice (19). Mice were divided into three groups (n = 6
in each group). The first group served as control (received an appropriate volume of 2%
gum acacia only, p.o.). The second group was standard (ketorolac, 0.33 mg kg–1 body
mass) and the third group, as the test group, received KD (KD1-KD4, 4.71, 3.30, 3.70 or
5.50 mg kg–1 body mass, respectively). Three hours after treatment, 0.6% (V/V) acetic
acid solution (10 mL kg–1) was injected to mice intraperitoneally. Total number of wri-
thes, which was a parameter of chemically induced pain (i.e., constriction of abdomen,
turning of trunk and extension of hind legs), was counted for 20 min. The analgesic ef-
fect was expressed as percent reduction of writhes in comparison with the control.
Anti-inflammatory activity. – The carrageenean induced rat hind paw edema assay de-
scribed by Winter et al. (20) was used to evaluate the acute anti-inflammatory activity of
the conjugates. Rats were divided into control, standard and test groups of six animals
each. Initial paw volumes of all animals were measured using a mercury plethysmometer
before treatment. Control group was given no drug but received only 2% gum acacia orally
in an appropriate volume. Standard group received ketorolac (0.33 mg kg–1 body mass,
p.o.) while KD (KD1-KD4, 4.71, 3.30, 3.70 or 5.50 mg kg–1 body mass, respectively, p.o.) was
administered to the test group. One hour after treatment, 0.1 mL of 1% (m/V) carrageenean
solution in distilled water was injected into the plantar region of the left hind paw of each
rat. The relative increase in paw volume was determined by measuring the paw volume
after 3 h following the carrageenean administration. The percent inhibition of edema, as
an indication of anti-inflammatory activity was compared with the controls.
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Ulcerogenicity studies. – The ulcerogenic activity was assessed using the method
adopted by Shanbhag et al. (21) in rats. Albino rats were randomly distributed into three
groups (n = 6 in each group). Control received no drug while the standard group was
given ketorolac (6.6 mg kg–1 body mass, p.o.) and the test group received KD1-KD4 (94.2,
66, 74 or 110 mg kg–1 body mass, respectively, p.o.) for 3 days. The animals were fasted 8 h
pre-treatment and 4 h post-treatment. Food and water were available for the rest of the
time. Four hours after the last dose, the animals were sacrified and the abdomen was
opened. The stomach with 3 cm of duodenum was removed. The stomach was opened
and washed with distilled water. The mucus was wiped off and the number of lesions
was examined by means of a magnifying glass. The degree of mucosal damage and ul-
ceration in each stomach was scored as + (strong irritation identified by redness and in-
flammation), ++ (ulcers < 0.5 mm), +++ (ulcers > 0.5 mm) and ++++ (perforation).
Data analysis
All the biological evaluation data are expressed as mean ± SEM and statistically
evaluated by Student’s t-test to determine the significance of the difference between the
control group and the drug or conjugate treated group.
RESULTS AND DISCUSSION
An activated moiety N-acylimidazole of ketorolac (KAI) was synthesized by inter-
action of ketorolac with CDI, which then condensed with dextran of different molecular
masses (40000, 60000, 110000 and 200000) to obtain KD1, KD2, KD3 and KD4 conjugates,
respectively (Scheme 1). Due to the moisture sensitivity of CDI, the reaction was carried
out under anhydrous conditions. Ester linkage formed in the conjugates was confirmed
by the IR spectrum which revealed the presence of characteristic absorption bands at
3300 cm–1 (OH broad) and 1730 cm–1 (C=O ester) (Fig. 1). The amount of ketorolac in the
conjugates was estimated after complete hydrolysis of the conjugates in borate buffer
(pH 9) and indicated 7, 10, 9 and 6% (m/m) of drug in KD1, KD2, KD3 and KD4, respec-
tively. These results show that varying the dextran molecular mass does not signifi-
cantly influence the drug content. Chromatographic, spectral and average molecular
mass data indicate that ketorolac is covalently bound to the dextran and support forma-
tion of ketorolac-dextran conjugates. Qualitative solubility analysis showed that
ketorolac is poorly soluble in water and acidic medium (pH 1.2) while all its dextran
conjugates (with estimated drug contents) were found to be soluble in water, acidic (pH
1.2) and basic media (pH 9).
In vitro chemical (aqueous medium: pH 1.2, 7.4 and 9) and enzymatic (80% human
plasma pH 7.4) hydrolysis kinetics of KD were also studied at 37 ± 1 °C. Those studies
indicated no hydrolysis at pH 1.2 for 3 h; hydrolysis of KD proceeds slowly at pH 7.4
and in 80% human plasma whereas relatively much faster hydrolysis was observed at
pH 9. The half-lives are reported in Table II. Varying the molecular mass of dextran does
not influence the hydrolysis in vitro. The fact that hydrolysis kinetics showed nearly sim-
ilar half-lives for KD at pH 7.4 either water of human plasma (80% m/m) signifies that
hydrolysis is not catalyzed by plasma enzymes. High stability of dextran conjugates in
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acidic pH was also suggested by Ahmad et al. (14) and Shrivastava et al. (15). The high
susceptibility of dextran conjugates to hydrolysis in highly alkaline medium may be at-
tributed to intramolecular catalysis by neighboring hydroxyl groups or it might be re-
lated to the basic character of the carbohydrate alkoxide ions. Lack of plasma enzyme-
-mediated hydrolysis is most likely due to steric hindrance by the dextran backbone (13).
Analgesic activity investigated by acetic acid-induced writhing in mice showed that
conjugates reduce the number of writhes significantly in KD1-KD4 in comparison to the
control group (p < 0.05). The standard drug ketorolac (0.33 mg kg–1 body mass, p.o.) sho-
wed 55% analgesic activity whereas ketorolac-dextran conjugates (equimolar doses to
ketorolac, orally) showed analgesic activity ranging from 43 to 50%.
The percentage inhibition of carrageenean-induced rat hind paw edema three hours
post-dosing of ketorolac (0.33 mg kg–1 body mass, p.o.) was found to be 57% while keto-
rolac-dextran conjugates (equimolar doses to ketorolac) showed 51, 50, 52 and 49% inhi-
bition in KD1-KD4, respectively.
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a Dose equimolar to the parent drug calculated on the basis of drug contents.
b Mean ± SEM, n = 6.
c Change in paw volume 3 h after carrageenean injection.
d p < 0.05 vs. control.
Analgesic and anti-inflammatory activities are reported in Table III. The results of
these biological evaluation indicate that conjugates have retained analgesic and anti-
inflammatory activities comparable that of the parent drug.
Animals did not show any gross behavioral changes, sedation, morbidity or mortal-
ity for 72 h at the administered oral doses of ketorolac or its conjugates used for analge-
sic and anti-inflammatory activities. The ulcerogenic activity study indicated that all the
ketorolac dextran conjugates showed remarkable decrease in ulcerogenic property com-
pared to their parent drug; moreover, KD2 and KD4 showed only irritation without any
ulceration. Results of ulcerogenicity studies indicate that dextran conjugates of ketorolac
showed remarkably reduced ulcerogenicity compared to ketorolac itself (Table IV).
CONCLUSIONS
In conclusion, the present investigations suggest that the ketorolac-dextran conju-
gates can represent potentially useful polymeric conjugates for oral administration of
ketorolac with improved water solubility and remarkably decreased gastro-intestinal
side-effects while retaining comparable pharmacological activities of the parent drug.
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a Dose equimolar to the parent drug calculated on the basis of drug contents.
b Ulcers > 0.5 mm; mean ± SEM, n = 6.
c + – strong irritation, ++ – ulcers < 0.5 mm, +++ – ulcers > 0.5 mm, ++++ – perforation.
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S A @ E T A K
Ketorolak-dekstran konjugati: sinteza, in vitro i in vivo vrednovanje
SAVITA VYAS, PIYUSH TRIVEDI i SUBHASH CHANDRA CHATURVEDI
U radu je opisana sinteza konjugata dektrana i protuupalnog lijeka ketorolaka (KD).
Konjugati su pripravljeni da bi se pove}ala topljivost ketorolaka u vodi i smanjile njego-
ve nuspojave u gastrointestinanom traktu. Ketorak je prvo preveden u N-acilimidazolni
derivat (KAI) koji je kondenziran s polimernim nosa~em, dekstranom razli~itih molekul-
skih masa (40000, 60000, 110000 i 200000). IR-spektri potvrdili su nastajanje esterske ve-
ze. Udio ketorolaka u konjugatu odre|en je UV-spektrofotometrijskom analizom. Mole-
kulske mase odre|ene su mjerenjem viskoznosti koriste}i Mark-Howink-Sakurada
jednad`bu. Hidroliza in vitro pra}ena je u puferskim otopinama (pH 1,2, 7,4 i 9) i u 80%
V/V humanoj plazmi (pH 7,4). Pri pH 9 primje}eno je zna~ajno br`e osloba|anje ketoro-
laka iz KD nego u puferskoj otopini pH 7,4 i krvnoj plazmi. Osloba|anje prati kinetiku
prvog reda. In vivo biolo{ka ispitivanja na mi{evima i {takorima ukazuju na to da konju-
gati imaju analgetsko i protuupalno djelovanje, a zna~ajno smanjeno ulcerogeno djelo-
vanje.
Klju~ne rije~i: ketorolak-dekstran konjugati, dekstranski nosa~, protuupalni nesteroidni lijekovi
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